Early data show faster viral clearance and favourable safety in mild to moderate COVID‑19
News
FDA approves once‑weekly Sogroya for wider paediatric use
New authorisation extends treatment to children with ISS, SGA and Noonan syndrome
SolasCure trial shows faster healing with Aurase Wound Gel
Phase 2 study reports significantly accelerated debridement and wound repair in venous leg ulcers
Gilead data show investigational HIV combination maintains viral suppression
New phase 3 results highlight potential alternative for adults switching from complex regimens
Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
More than 200 participants enrolled as company targets topline data by end of 2026
MHRA approves imlunestrant tosylate as new breast cancer treatment
Oral therapy authorised for ER‑positive, HER2‑negative metastatic disease with ESR1 mutations
ACD440 granted orphan drug status in the EU
Erythromelalgia treatment gains regulatory support following EMA decision
ViiV Healthcare data show lower rates of steatotic liver disease after switching to Dovato
PASO DOBLE sub‑analysis indicates metabolic differences between 2‑drug and 3‑drug HIV regimens
Tremfya data show sustained remission in ulcerative colitis through 3 years
QUASAR long‑term extension results highlight durable clinical and endoscopic outcomes
Brensocatib becomes first licensed treatment for non‑cystic fibrosis bronchiectasis
MHRA authorises medicine for patients aged 12 and over with repeated flare‑ups
Lario Therapeutics awarded $2.4m to advance calcium channel platform
Funding from MJFF and Wellcome supports expansion into Parkinson’s and PTSD
Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection
Basque company becomes first authorised under new European SoHO rules
Exdensur approved in EU for severe asthma and CRSwNP
European Commission backs first ultra‑long‑acting biologic for respiratory disease
Axol Bioscience acquires Newcells Biotech ophthalmology unit
Move expands iPSC‑derived retinal model portfolio and strengthens position in research
Nuclera and leadXpro partner to accelerate structure‑based drug design
Collaboration aims to speed access to challenging targets through an AI‑guided workflow
